Historical Valuation
SIMCERE PHARMA (02096) is now in the Fair zone, suggesting that its current forward PE ratio of 19.59 is considered Fairly compared with the five-year average of 19.24. The fair price of SIMCERE PHARMA (02096) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：11.62
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
SIMCERE PHARMA (02096) has a current Price-to-Book (P/B) ratio of 3.66. Compared to its 3-year average P/B ratio of 2.60 , the current P/B ratio is approximately 41.03% higher. Relative to its 5-year average P/B ratio of 2.88, the current P/B ratio is about 27.01% higher. SIMCERE PHARMA (02096) has a Forward Free Cash Flow (FCF) yield of approximately 3.78%. Compared to its 3-year average FCF yield of 2.75%, the current FCF yield is approximately 37.33% lower. Relative to its 5-year average FCF yield of 1.58% , the current FCF yield is about 139.39% lower.
Performance Decomposition
AI Analysis
1Y
3Y
5Y
Market capitalization of 02096 increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of 02096 in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is 02096 currently overvalued or undervalued?
SIMCERE PHARMA (02096) is now in the Fair zone, suggesting that its current forward PE ratio of 19.59 is considered Fairly compared with the five-year average of 19.24. The fair price of SIMCERE PHARMA (02096) is between to according to relative valuation methord.
What is SIMCERE PHARMA (02096) fair value?
02096's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of SIMCERE PHARMA (02096) is between to according to relative valuation methord.
How does 02096's valuation metrics compare to the industry average?
The average P/S ratio for 02096's competitors is , providing a benchmark for relative valuation. SIMCERE PHARMA Corp (02096) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for SIMCERE PHARMA (02096) as of Jan 15 2026?
As of Jan 15 2026, SIMCERE PHARMA (02096) has a P/B ratio of 3.66. This indicates that the market values 02096 at 3.66 times its book value.
What is the current FCF Yield for SIMCERE PHARMA (02096) as of Jan 15 2026?
As of Jan 15 2026, SIMCERE PHARMA (02096) has a FCF Yield of 3.78%. This means that for every dollar of SIMCERE PHARMA’s market capitalization, the company generates 3.78 cents in free cash flow.
What is the current Forward P/E ratio for SIMCERE PHARMA (02096) as of Jan 15 2026?
As of Jan 15 2026, SIMCERE PHARMA (02096) has a Forward P/E ratio of 19.59. This means the market is willing to pay $19.59 for every dollar of SIMCERE PHARMA’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for SIMCERE PHARMA (02096) as of Jan 15 2026?
As of Jan 15 2026, SIMCERE PHARMA (02096) has a Forward P/S ratio of 3.43. This means the market is valuing 02096 at $3.43 for every dollar of expected revenue over the next 12 months.